Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.RegeneRx Biopharmaceuticals has said that researchers at the Wayne State University School of Medicine and the Kresge Eye Institute in Detroit, Michigan have found Thymosin beta 4 to be an effective corneal wound healing and anti-inflammatory agent. Researchers at the Peking Union Medical College in Bejing, China, have also reported that recombinant thymosin beta 4 can promote full thickness dermal wound healing.
Subscribe to our email newsletter
According to the researchers: “Treatment with thymosin beta 4 resulted in increased re-epithelialization and considerable capillary in-growth. Vessel counts showed a significant increase in the number of vessels in the thymosin beta 4 treated wounds. We also observed an increase in the deposition/accumulation of collagen in the thymosin beta 4-treated wounds.”
Dr Gabriel Sosne, whose research team has conducted the corneal research on thymosin beta 4 and who is a member of RegeneRx’s medical and scientific advisory board, said: “The data supporting the use of thymosin beta 4 as a wound healing and anti-inflammatory agent continues to accumulate, confirmed by independent researchers throughout the world in ophthalmic, dermal and cardiovascular tissues.”